BCA
AXDX

Berman Capital Advisors’s Accelerate Diagnostics AXDX Stock Holding History

Berman Capital Advisors’s Portfolio AXDX Stock Details AXDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-5
Closed -$1K – 1447
2019
Q2 		$1K Buy
+5
New +$978 ﹤0.01% 1300

Other funds holding AXDX

OIM
Oracle Investment Management Greenwich, Connecticut $168M AUM 42.86% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
BC
Birchview Capital Burlington, Vermont $214M AUM 185.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Axa
Axa Paris, France $91.9M AUM 27.41% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
CC
Cannell & Co New York $3.15B AUM 30.62% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $2.4B AUM 42.85% 1-Year Est. Return
CC
Chicago Capital Chicago, Illinois $4.15B AUM 31.09% 1-Year Est. Return

Berman Capital Advisors's AXDX Position: Q3 2019 in Review

Berman Capital Advisors sold out of Accelerate Diagnostics (AXDX) in Q3 2019, closing a stake of 5 shares — an estimated $1K sold.

Berman Capital Advisors first reported a position in AXDX in Q2 2019 and held it in 1 quarter. The position peaked at $1K in Q2 2019. 113 funds tracked by Wall St. Rank hold AXDX as of Q3 2019.

  • Berman Capital Advisors reported no remaining Accelerate Diagnostics position as of Q3 2019 after selling out during the quarter.
  • Berman Capital Advisors sold 5 Accelerate Diagnostics shares in Q3 2019, an estimated $1K.
  • Berman Capital Advisors first reported a position in Accelerate Diagnostics in Q2 2019 and held it in 1 quarter.
  • Berman Capital Advisors's Accelerate Diagnostics position peaked at $1K in Q2 2019.
  • 113 funds tracked by Wall St. Rank held Accelerate Diagnostics as of Q3 2019.

Based on Berman Capital Advisors's 13F filing for Q3 2019, filed 14 Nov 2019.